Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025

Core Insights - Amplia Therapeutics Limited is making significant progress in the clinical development of its FAK inhibitor, narmafotinib, particularly for metastatic pancreatic cancer, with promising results from ongoing trials [2][3][17] Clinical Trial Updates - The ACCENT trial, which combines narmafotinib with gemcitabine and Abraxane®, has reported an overall response rate of 35%, significantly higher than the 23% response rate for chemotherapy alone [3][17] - The mean duration on trial for patients was 219 days, with some patients remaining on the study for over 12 months, indicating the drug's potential to halt cancer progression [4] - The AMPLICITY trial has commenced, investigating narmafotinib in combination with FOLFIRINOX chemotherapy, with patient recruitment ongoing in Melbourne and Sydney [6][7] Regulatory and Commercial Developments - Positive feedback from the US FDA has been received regarding the dose optimization strategy for narmafotinib, which supports its planned Phase 2b/3 trial [8] - A key patent for narmafotinib has been granted, extending protection until at least 2040 in the US and other jurisdictions [9] - Amplia has successfully uplisted to the US-based OTCQB Venture Market, enhancing its visibility and investor reach [10] Preclinical Studies - The second phase of a research collaboration with Next & Bio has been initiated, focusing on evaluating narmafotinib against patient-derived pancreatic cancer cells with specific genetic mutations [11] Financial Update - Amplia reported a cash position of $31.5 million at the end of December 2025, with net operating cash inflows of $2.4 million during the quarter [13] - The company received $3.8 million from government grants and tax incentives, while outflows included $0.9 million for staff and administration costs, and $0.9 million for research and development [14]